Status:
UNKNOWN
The Novel 18F-labeled MAO-B PET Tracer Study in Parkinsonism Patients
Lead Sponsor:
Anhui Provincial Hospital
Conditions:
Parkinson Disease
Eligibility:
All Genders
40-90 years
Brief Summary
This study mainly aims to prospectively evaluate the changes of reactive astrogliosis in Parkinsonism patients of Chinese population by the novel 18F-labeled MAO-B PET tracer.
Detailed Description
18F-SMBT-1, the novel 18F-labeled MAO-B PET tracer, was evaluated reactive astrogliosis in Alzheimer's disease successfully. In this prospective study, we assess the changes of reactive astrocytes in ...
Eligibility Criteria
Inclusion
- Aged from 40 to 90 years old.
- Clinically diagnosed as Parkinsonism, including Parkinson's disease and atypical Parkinsonism syndromes.
- Can cooperate with 18F-FDG PET/CT, 18F-FP-CIT PET/CT and 3D T1-weighted structural MR scans.
- Complete clinical data, including modified Hoehn and Yahr staging scale and the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
Exclusion
- Cannot cooperate with PET/CT or MR examination.
- Associated with brain diseases such as stroke, brain trauma, brain tumor, and cranial surgery.
Key Trial Info
Start Date :
November 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06010290
Start Date
November 30 2022
End Date
December 31 2023
Last Update
August 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of China University of Science and Technology
Hefei, Anhui, China, 230000